Navigation Links
Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
Date:4/16/2008

lieve we will benefit enormously from his wealth of drug development experience," said Dr. Kontzalis, Chief Executive Officer for ANAVEX. "Dr. Goundis' successful track record in clinical trials and his proven achievements in accelerating drug development programs will provide critical support for our business objectives as we look to file Investigational New Drug applications for three lead drug candidates and commence Phase 1 clinical trials of our lead Alzheimer's compound over the next 12 months."

"I am pleased to join the ANAVEX team at such a critical juncture in the company's growth and to be leading the development of a group of novel drug compounds with disease-modifying potential," said Dr. Goundis. "ANAVEX's approach to treating diseases is unique and unmatched in the industry. Our drug candidates have the potential to be safer and more effective than medications currently on the market because they aim to modify and treat the underlying causes, as opposed to just the symptoms, of Alzheimer's, epilepsy and various types of cancer.

Prior to joining ANAVEX, Dr. Goundis spent six years in various management roles with his most recent as Managing Director at Speedel Experimenta, the late-stage research unit of public biopharmaceutical company Speedel AG. During his tenure, Dr. Goundis led the successful development of SPP100 from Phase I through Phase IIb clinical trials, at which time Novartis exercised its license-back option. Today, SPP100 is sold in the United States under the trade name Tekturna and in Europe under the name Rasilez to treat hypertension. In addition, Dr. Goundis spent several years with lead responsibility for the company's entire development portfolio, including compounds in Phases I, II and III.

Dr. Goundis' background also includes director-level positions with The Medicines Company, where he was responsible for leading and managing the CNS business unit, and Roche, where he managed projects across a variety of th
'/>"/>

SOURCE Anavex Life Sciences Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
2. Anavex strengthens Board of Directors
3. Anavex advances drug candidate for treatment of Alzheimers disease
4. Phytomedics Inc. Appoints Dr. Laurie Smaldone Alsup, MD., as President and Chief Executive Officer
5. Metabolex Appoints Donald Hill as Chief Financial Officer
6. Biopure Appoints New Independent Auditor
7. Indivumed Appoints Annette Kassen as Vice President Clinical Research
8. ADVENTRX Appoints Vice President of Manufacturing
9. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
10. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
11. Observant LLC Appoints Two New Directors to the Senior Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... A new study published today in the journal ... has found that time of day and sleep deprivation ... could be crucial when looking at the best time ... and heart disease, and for administering medicines effectively. , ... of Cancer Research, London, investigated the links between sleep ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
... CRANBURY, N.J., March 11 Amicus Therapeutics (Nasdaq: ... and Chief Executive Officer John F. Crowley will be ... Healthcare Conference. Mr. Crowley,s presentation is scheduled to ... Time.Individuals can listen to a live webcast of the ...
... CITY, March 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... on endocrinology and oncology, today reported financial and operating results for ... 2008 Highlights, - February, ... a Phase 2 trial in advanced, ...
... Wednesday, March 11, 2009 at 4:30 p.m. Eastern TimeBOTHELL, ... Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI ... 2008 financial results, reviewed the Company,s highlights and provided ... active year from an execution standpoint as we took ...
Cached Biology Technology:AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 2AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 3AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 4AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 5AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 6AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 7AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 8AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 9AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 2OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 3OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 4OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 5OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 6OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 7OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 8OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 9OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 10OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 11OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009 12
(Date:7/10/2014)... of overfishing in the English Channel has resulted in ... and left fishermen ,scraping the barrel, for increasing amounts ... cod, haddock and many other species at the head ... many removed from the area completely., These are some ... biologists at Plymouth University, in association with international non-profit ...
(Date:7/10/2014)... even if you are a big, bad sea scorpion. ... shallow waters for any prey in sight. The next, ... scientists, you,re reduced to trolling for weaker, soft-bodied animals ... lot of the giant pterygotid eurypterid, the largest arthropod ... published in the journal Biology Letters , dramatically ...
(Date:7/10/2014)... Endomedix, a start-up company housed at NJIT,s business incubator, ... spray-on gel that surgeons will use to staunch bleeding ... onto a surgical site, and the natural bio-polymer solutions ... the patient within 30 seconds. , The gel ... It will translate into less time for the patient,s ...
Breaking Biology News(10 mins):Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 2Overfishing in the English Channel leaves fisherman scraping the bottom of the barrel 3Extinct sea scorpion gets a Yale eye exam, with surprising results 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... effect of cocaine on mice by genetically manipulating a ... , While the researchers aren't suggesting that these genetic ... light the key protein that controls cocaine's effects in ... achieve the same results and therefore help addicts overcome ...
... plant species are not only more productive, they are ... extremes, pests and disease over long periods of time. ... of Nature, are the culmination of 12 years of ... at the University of Minnesota, to explore the value ...
... the genes in the fruitfly genome, Johns Hopkins scientists have ... and simultaneously captured a global view of all the genes ... The study, to be published April 3 in Developmental Cell, ... cells that move similarly to spread beyond an original tumor, ...
Cached Biology News:Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3Biodiversity key to sustainable biofuel according to University of Minn. researcher's findings 2Researchers identify genes in fruitflies that may shed light on human cancer spread 2
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Full length YebU (Escherichia coli)...
Request Info...
Human Cell Line Slides...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: